BioLineRx Ltd. (NASDAQ:BLRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

Other research analysts have also recently issued reports about the company. ValuEngine raised BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Roth Capital assumed coverage on BioLineRx in a research note on Thursday, August 3rd. They set a “buy” rating and a $3.00 target price for the company. Maxim Group set a $3.00 target price on BioLineRx and gave the stock a “buy” rating in a research note on Tuesday, August 8th. HC Wainwright set a $4.00 target price on BioLineRx and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Finally, Oppenheimer Holdings, Inc. assumed coverage on BioLineRx in a research note on Friday, August 4th. They set an “outperform” rating and a $3.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. BioLineRx currently has an average rating of “Buy” and an average target price of $2.59.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.05).

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/21/biolinerx-ltd-blrx-lifted-to-hold-at-zacks-investment-research.html.

Several large investors have recently added to or reduced their stakes in BLRX. Citadel Advisors LLC boosted its position in shares of BioLineRx by 443.4% during the 1st quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 86,481 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of BioLineRx during the 1st quarter worth about $126,000. KCG Holdings Inc. boosted its position in shares of BioLineRx by 715.9% during the 1st quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 153,687 shares in the last quarter. Finally, Sabby Management LLC acquired a new position in shares of BioLineRx during the 1st quarter worth about $3,018,000. 32.27% of the stock is owned by institutional investors and hedge funds.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.